Relmada Therapeutics, Inc. · NASDAQ:RLMD
Squadron Capital Management LLC's stake in Relmada Therapeutics, Inc. fell to 3.30% (Schedule 13G/A)
Event Sep 30, 2026 · Filed Nov 16, 2026
Squadron Capital Management LLC's stake in Relmada Therapeutics, Inc. fell to 3.30%, 3,500,000 shares, as a passive investor on Sep 30, 2026. Filed Nov 16, 2026 (Schedule 13G/A).
- Stake
- 3.30%
- Shares
- 3,500,000
- Intent
- Passive
- What changed
- Fell below 5%
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Squadron Master Fund LP | 3.30% | 3,500,000 |
| Squadron Capital Management LLC | 3.30% | 3,500,000 |
| Matthew Sesterhenn | 3.30% | 3,500,000 |
| William Blank | 3.30% | 3,500,000 |
Source
Download original · View original at SEC
Related
- Relmada Therapeutics, Inc.
- Squadron Capital Management LLC
- Relmada Therapeutics, Inc. shareholders
- Schedule 13G/A · Squadron Capital Management LLC · Aug 14, 2026
- Schedule 13G/A · Squadron Capital Management LLC · Feb 17, 2026
- Schedule 13G/A · Squadron Capital Management LLC · Aug 14, 2025
- Schedule 13G · Squadron Capital Management LLC · May 1, 2025
- Form 4 · Shenouda Maged · Sep 11, 2026
- Form 4 · Traversa Sergio · Sep 11, 2026
- Schedule 13G · BlackRock, Inc. · Jul 29, 2026
- Schedule 13G · Millennium Management LLC · Jun 22, 2026
- Schedule 13G · Venrock Healthcare Capital Partners III, L.P. · Jun 9, 2026